A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong.
A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong.